Oral Paricalcitol versus Calcitriol in Peritoneal Dialysis Patients: effects on peritoneal transport and peritoneal defence
Completed
- Conditions
- Verstoring peritoneale homeostase door peritoneaaldialysePeritoneal damage due to peritoneal dialysis
- Registration Number
- NL-OMON37926
- Lead Sponsor
- Vrije Universiteit Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 24
Inclusion Criteria
· the patient must provide written consent prior to starting the study
· patients must be over 18 years of age
· patients must have CKD stage 5 and treatment with peritoneal dialysis
· indication for active vitamin D therapy based on prevailing guidelines (after 6 weeks of wash-out)
· Calcium, corrected to albumen, < 2.6 mmol/l (after 6 weeks of wash-out)
· Not expected to receive a living donor transplant < 6 months
Exclusion Criteria
· Patients who do not meet the specific inclusion criteria.
· UF < 1000 ml/24h with 4 3.86%/4.25% glucose exchanges or impossibility to stop Extraneal
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Endpoints are differences (25% or more) in markers of inflammation and<br /><br>peritoneal transport between the paricalcitol and alphacalcidol groups. </p><br>
- Secondary Outcome Measures
Name Time Method <p>None</p><br>